1. Home
  2. RSF vs CVM Comparison

RSF vs CVM Comparison

Compare RSF & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RSF
  • CVM
  • Stock Information
  • Founded
  • RSF 2016
  • CVM 1983
  • Country
  • RSF United States
  • CVM United States
  • Employees
  • RSF N/A
  • CVM N/A
  • Industry
  • RSF Investment Managers
  • CVM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RSF Finance
  • CVM Health Care
  • Exchange
  • RSF Nasdaq
  • CVM Nasdaq
  • Market Cap
  • RSF 62.5M
  • CVM 63.3M
  • IPO Year
  • RSF N/A
  • CVM 1987
  • Fundamental
  • Price
  • RSF N/A
  • CVM $10.24
  • Analyst Decision
  • RSF
  • CVM
  • Analyst Count
  • RSF 0
  • CVM 0
  • Target Price
  • RSF N/A
  • CVM N/A
  • AVG Volume (30 Days)
  • RSF 11.8K
  • CVM 138.3K
  • Earning Date
  • RSF 01-01-0001
  • CVM 08-14-2025
  • Dividend Yield
  • RSF 10.61%
  • CVM N/A
  • EPS Growth
  • RSF N/A
  • CVM N/A
  • EPS
  • RSF N/A
  • CVM N/A
  • Revenue
  • RSF N/A
  • CVM N/A
  • Revenue This Year
  • RSF N/A
  • CVM N/A
  • Revenue Next Year
  • RSF N/A
  • CVM N/A
  • P/E Ratio
  • RSF N/A
  • CVM N/A
  • Revenue Growth
  • RSF N/A
  • CVM N/A
  • 52 Week Low
  • RSF $14.81
  • CVM $1.98
  • 52 Week High
  • RSF $16.23
  • CVM $32.70
  • Technical
  • Relative Strength Index (RSI)
  • RSF 51.11
  • CVM 56.70
  • Support Level
  • RSF $14.59
  • CVM $8.69
  • Resistance Level
  • RSF $14.89
  • CVM $10.83
  • Average True Range (ATR)
  • RSF 0.08
  • CVM 0.61
  • MACD
  • RSF 0.01
  • CVM 0.05
  • Stochastic Oscillator
  • RSF 52.86
  • CVM 76.99

About RSF RiverNorth Capital and Income Fund

RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.

About CVM Cel-Sci Corporation

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

Share on Social Networks: